Quality of Life in Schizophrenic Patients (Quality)

June 8, 2010 updated by: AstraZeneca

QUALITY: A Non-interventional Study Evaluating Quality Of Life in Schizophrenic Patients Treated With Atypical Antipsychotics, in the Ambulatory Setting. A 9-month, Observational, Multicentric Prospective Study.

This is a non-interventional study evaluating quality of life in schizophrenic patients treated with atypical antipsychotics, in the ambulatory setting. This is a 9-month, observational, multicentric prospective study.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

124

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Aalst, Belgium
        • Research Site
      • Asse, Belgium
        • Research Site
      • Bertrix, Belgium
        • Research Site
      • Bierbeek, Belgium
        • Research Site
      • Boechout, Belgium
        • Research Site
      • Bon-secours, Belgium
        • Research Site
      • Bruxelles, Belgium
        • Research Site
      • Dendermonde, Belgium
        • Research Site
      • Diest, Belgium
        • Research Site
      • Duffel, Belgium
        • Research Site
      • Eeklo, Belgium
        • Research Site
      • Elsene, Belgium
        • Research Site
      • Embourg, Belgium
        • Research Site
      • Floreffe, Belgium
        • Research Site
      • Gent, Belgium
        • Research Site
      • Halle, Belgium
        • Research Site
      • Henri-Chapelle, Belgium
        • Research Site
      • Herstal, Belgium
        • Research Site
      • Jambes, Belgium
        • Research Site
      • Kortenberg, Belgium
        • Research Site
      • Kortrijk, Belgium
        • Research Site
      • La Louviere, Belgium
        • Research Site
      • Leut, Belgium
        • Research Site
      • Leuven, Belgium
        • Research Site
      • Libramont, Belgium
        • Research Site
      • Liege, Belgium
        • Research Site
      • Lierneux, Belgium
        • Research Site
      • Melle, Belgium
        • Research Site
      • Menen, Belgium
        • Research Site
      • Mol, Belgium
        • Research Site
      • Mons, Belgium
        • Research Site
      • Oostende, Belgium
        • Research Site
      • Ottignies, Belgium
        • Research Site
      • Roeselare, Belgium
        • Research Site
      • Schaerbeek, Belgium
        • Research Site
      • Sint-Kruis (Brugge), Belgium
        • Research Site
      • Sint-Lambrechts-Woluwe, Belgium
        • Research Site
      • Sint-Michiels, Belgium
        • Research Site
      • Sint-Niklaas, Belgium
        • Research Site
      • Sint-Truiden, Belgium
        • Research Site
      • Sleidinge, Belgium
        • Research Site
      • Tielt, Belgium
        • Research Site
      • Tienen, Belgium
        • Research Site
      • Veurne, Belgium
        • Research Site
      • Waregem, Belgium
        • Research Site
      • Woluwe-Saint-Lambert, Belgium
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Ambulatory patients

Description

Inclusion Criteria:

  • Patients diagnosed with Schizophrenia treated with atypical antipsychotics (ambulatory patients).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change from baseline of QOL assessed by the SWN-K after 9 months of treatment with AAPs.
Time Frame: 9 months
9 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Principal Investigator: Prof Vermylen, UZ Leuven

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2007

Primary Completion (Actual)

October 1, 2009

Study Completion (Actual)

October 1, 2009

Study Registration Dates

First Submitted

November 28, 2007

First Submitted That Met QC Criteria

January 16, 2008

First Posted (Estimate)

January 17, 2008

Study Record Updates

Last Update Posted (Estimate)

June 9, 2010

Last Update Submitted That Met QC Criteria

June 8, 2010

Last Verified

June 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIS-NBE-SER-2006/1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe